Apellis Pharmaceuticals

About:

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

Website: http://www.apellis.com

Twitter/X: ApellisPharma

Top Investors: F-Prime Capital, Cormorant Asset Management, Morningside Venture Investments, Sofinnova Investments, Sixth Street

Description:

Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.